Chemotherapy-Induced Neutropenia Market to Reach $0.79B by 2030 at 5.1% CAGR
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Projected Increase In Market Value Of The Chemotherapy-Induced Neutropenia Treatment Market During 2026–2030?
The market for chemotherapy-induced neutropenia treatment has experienced robust expansion in recent times. Projections indicate its size will increase from $0.62 billion in 2025 to reach $0.65 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 5.3%. Historically, this growth can be ascribed to several factors, including the increasing incidence of chemotherapy-induced neutropenia, the expansion of aggressive cancer treatment protocols, the availability of colony-stimulating factors, advancements in clinical monitoring practices, and the proliferation of oncology treatment facilities.
The chemotherapy-induced neutropenia treatment market is anticipated to show significant expansion in the forthcoming years. It is forecast to grow to $0.79 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.1%. This growth during the forecast period is attributable to several factors, including the increasing adoption of long-acting growth factors, a rising focus on managing neutropenia in outpatient settings, the broader usage of biosimilar G-CSF, increased investment in strategies for infection prevention, and advancements in immunomodulatory therapies. Major trends expected in this period involve a greater adoption of prophylactic G-CSF therapy, an increased utilization of early intervention treatment models, a growing emphasis on reducing infection risks, the expansion of personalized neutropenia management approaches, and enhanced monitoring of white blood cell levels.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Drivers Are Supporting The Chemotherapy-Induced Neutropenia Treatment Market Growth?
The rising occurrence of cancer is projected to fuel the expansion of the chemotherapy-induced neutropenia treatment market in the future. Cancer is defined as a collection of illnesses marked by the unregulated proliferation and dissemination of atypical cells within the body. The increase in cancer diagnoses stems from an aging demographic, given that elderly people face a greater likelihood of contracting cancer due to a buildup of genetic changes and a diminished immune system over their lifespan. Treatment for chemotherapy-induced neutropenia supports cancer care by lowering the danger of infections via immunological assistance, thereby enabling patients to proceed with chemotherapy with less frequent pauses. This treatment also improves therapeutic results by reducing complications, consequently elevating patient safety and overall quality of life. As an illustration, data from July 2024, provided by the Australian Institute of Health and Welfare, an Australian government body, indicated that approximately 165,000 Australians received a new cancer diagnosis in 2023, translating to more than 450 daily cases, with males accounting for roughly 55% of these new diagnoses. Consequently, the growing frequency of cancer cases is stimulating the expansion of the chemotherapy-induced neutropenia treatment market.
What Segment Categories Shape The Chemotherapy-Induced Neutropenia Treatment Market Segment Landscape?
The chemotherapy-induced neutropenia treatment market covered in this report is segmented –
1) By Type: Antibiotic Therapy, Granulocyte Colony-Stimulating Factor Therapy (G-CSF), Granulocyte Transfusion, Other Types
2) By Route of Administration: Subcutaneous, Intravenous
3) By Indication: Solid Tumors, Hematological Malignancies, Other Indications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Specialty Clinics, Homecare Settings
Subsegments:
1) By Antibiotic Therapy: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics, Prophylactic Antibiotics
2) By Granulocyte Colony-Stimulating Factor Therapy (G-CSF): Filgrastim, Pegfilgrastim, Lenograstim
3) By Granulocyte Transfusion: Allogeneic Granulocyte Transfusion, Autologous Granulocyte Transfusion
4) By Other Types: Antifungal Therapy, Stem Cell Therapy, Immunomodulatory Therapy
Which Trends Are Expected To Impact The Chemotherapy-Induced Neutropenia Treatment Market?
Leading companies within the chemotherapy-induced neutropenia treatment market are concentrating their efforts on developing and securing approvals for innovative products, notably long-acting formulations, to enhance patient convenience, decrease dosing frequency, and improve adherence to treatment. These long-acting formulations are drug preparations designed to gradually release active ingredients over an extended duration, thereby reducing the necessity for frequent administration. For example, in December 2023, Coherus BioSciences Inc., a US-based biopharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for Udenyca Onbody, an innovative, ready-to-use on-body injector. This device, featuring a long-acting formulation, automatically delivers pegfilgrastim approximately 27 hours post-chemotherapy, eliminating the need for a subsequent day injection. Udenyca Onbody significantly elevates the patient experience by ensuring timely prophylactic treatment for chemotherapy-induced neutropenia, while also minimizing clinic visits and boosting adherence.
Who Are The Companies Operating Across The Chemotherapy-Induced Neutropenia Treatment Market Value Chain?
Major companies operating in the chemotherapy-induced neutropenia treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., GSK plc, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Baxter Inteational, Fresenius Kabi, Eisai Co. Ltd., Dr. Reddy’s Laboratories Ltd., Exelixis Inc., Biocon Biologics Limited, Coherus BioSciences Inc., G1 Therapeutics, Enzychem Lifesciences Corporation
Get The Full Chemotherapy-Induced Neutropenia Treatment Market Report:
Which Region Is The Leading Market For The Chemotherapy-Induced Neutropenia Treatment Market?
North America was the largest region in the chemotherapy-induced neutropenia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced neutropenia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Chemotherapy-Induced Neutropenia Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Chemotherapy-Induced Neutropenia Treatment Market 2026, By The Business Research Company
Chemotherapy Induced Peripheral Neuropathy Treatment Market Report 2026
Chemotherapy Induced Anemia Market Report 2026
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report
Chemotherapy Induced Myelosuppression Treatment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
